SPL is downregulated in prostate and colon cancer (71, 72, 76), and it was shown to have an implication in chemo and radiotherapy resistance (76), implying that regulation of SPL activity might be a novel approach to cancer treatment. This evidence concerns the gene SGPL1 and cancer.